当前位置: X-MOL 学术Pept. Sci. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cover Image, Volume 112, Issue 3
Peptide Science ( IF 2.4 ) Pub Date : 2020-05-27 , DOI: 10.1002/pep2.24174


Worm et al. review recent developments in targeted cancer therapy. Peptide‐binding G protein‐coupled receptors (GPCRs) overexpressed in cancerous tissue can be addressed by peptide ligands, which in turn can serve as tumour‐selective carriers for use in peptide‐drug conjugates (PDCs). PDCs contain the peptide coupled to a smart linker that facilitates the controlled release of the attached drug. The drug can be a specific toxophore, radiolabel or boron‐10 for boron neutron capture therapy. The receptor‐PDC complex selectively binds to the cells that overexpress the targeted GPCR and is internalised, thus facilitating the drug to enter tumour cells while sparing healthy tissue. (doi: 10.1002/pep2.24171)
image


中文翻译:

封面图片,第112卷,第3期

蠕虫。回顾靶向癌症治疗的最新进展。在癌组织中过表达的肽结合G蛋白偶联受体(GPCR)可以通过肽配体解决,肽配体又可以用作肿瘤选择性载体,用于肽-药物偶联物(PDC)。PDC包含与智能接头连接的肽,该接头有助于受控药物附着药物的释放。该药物可以是用于硼中子捕获疗法的特定毒素,放射性标记或硼10。受体-PDC复合物选择性地与过量表达靶向GPCR的细胞结合并被内在化,从而促进药物进入肿瘤细胞,同时保留健康的组织。(doi:10.1002 / pep2.24171)
图片
更新日期:2020-05-27
down
wechat
bug